oportuzumab monatox (Pending FDA Approval)

Brand and Other Names:Vicineum
Sections

Dosing & Uses

Bladder Cancer

Pending FDA approval as intravesical administration for high-risk BCG-unresponsive non-muscle invasive bladder cancer

Next:

Pharmacology

Mechanism of Action

Oportuzumab monatox is a recombinant fusion protein comprising a humanized anti-EpCAM single-chain antibody linked to Pseudomonas exotoxin A

Once bound to the cancer cell, the drug is internalized and the toxin moiety released into the cytosol where it induces apoptosis

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.